Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

IMPACT- 24Bt Post Mech. Thrombectomy and/or rtPA TRIAL IMPlant Augmenting Cerebral Blood Flow 24 Hours From Stroke Onset (IMPACT-24Bt)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01874093
Recruitment Status : Terminated
First Posted : June 10, 2013
Last Update Posted : June 26, 2018
Sponsor:
Information provided by (Responsible Party):
BrainsGate

Brief Summary:
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in a 24 hour window, in patients with an acute ischemic stroke in the anterior circulation, who received Mechanical Thrombectomy and/or IV-rtPA and Standard of Care.

Condition or disease Intervention/treatment Phase
Ischemic Stroke Device: The Ischemic Stroke System Device: Sham control Phase 3

Detailed Description:

This will be a multi-center, multinational, randomized, double blind, sham control, adjunctive to Standard of Care, parallel arm study and will include ongoing DSMB review of accumulated safety data.

The study has three phases:

Phase I - Implantation Safety Assessment

  • Number of patients: 20 (at least 10 implantations)
  • Implanters: only certified implanters who already performed implantation of ISS in previous studies
  • Continue to the next phase if there are no serious procedure complications related to IV-rtPA (as determined by the implanter). Otherwise, implement retirements and continue only after DSMB approval.

DSMB meetings: after 10 implantations

Phase II - Symptomatic Intracranial Hemorrhage Assessment (sICH):

  • Number of patients: 50 (additional 30)
  • Implanters: all certified implanters
  • Verify no clinically meaningful difference between treated and control. A clinically meaningful difference is a difference of more than 3 sICH cases within the first 5 days of treatment, in the treated arm compared to the control arm.

In case of clinically meaningful difference, implement retirements.

  • Continue to phase III after DSMB approval.
  • DSMB meetings: after 30 and 50 patients

Phase III - Entire study population, DSMB meetings at 100 and 150 patients

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-center, Rand., Double Blind, Sham Control, Parallel Arm Post Mech. Thrombectomy and/or rtPA Trial to Assess Safety and Effectiveness of the Ischemic Stroke System, as an Adjunct to Stand. of Care in Subjects With Acute Isch. Stroke
Study Start Date : May 2013
Actual Primary Completion Date : June 2018
Actual Study Completion Date : June 2018

Arm Intervention/treatment
Experimental: Active Stimulation
INS implantation, 5 Days of Ischemic Stroke System (ISS) Stimulation + Standard of Care
Device: The Ischemic Stroke System
SPG stimulation and standard of care

Sham Comparator: Sham Stimulation
Sham implantation, 5 Days of Sham Stimulation + Standard of Care
Device: Sham control
Sham stimulation and standard of care




Primary Outcome Measures :
  1. Distribution of patients across the ordinal modified Rankin scale (mRS) [ Time Frame: 90 days ]

    The primary effectiveness endpoint will be the modified Rankin Scale (mRS) evaluated by the site on Day 90±7.

    The statistical analysis of the primary effectiveness endpoint will be: Sliding Dichotomous mRS.



Secondary Outcome Measures :
  1. Distribution of patients with NIHSS best language score ≥ 2 at screening across the ordinal modified Rankin scale (mRS) [ Time Frame: 90 days ]

    The secondary effectiveness endpoint will be the modified Rankin Scale (mRS) evaluated by the site on Day 90±7 for patients with NIHSS best language score ≥ 2 at screening.

    The statistical analysis of the primary effectiveness endpoint will be: Sliding Dichotomous mRS.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age: ≥ 40 years and ≤ 80 years for male and 85 for female subjects
  2. Clinical diagnosis of an acute ischemic stroke in the Carotid, Middle or Anterior Cerebral Artery territories based on general physical examination and neurological examination.
  3. Imaging findings demonstrating signs of ischemia (or total arterial occlusion prior to the MT procedure) in the anterior circulation, consistent with the clinical diagnosis.
  4. Performance of MT within <8 hours from stroke onset and/or administration of IV-rtPA within ≤ 4.5 hours from stroke onset.
  5. NIHSS ≥ 7 and ≤ 18 within 2 hours prior to implantation.
  6. Ability to initiate treatment within

    ≤ 24 hours from stroke onset.

  7. Signed informed consent from patient him/herself or legally authorized representative if applicable.

Exclusion Criteria:

  1. Neuro-imaging evidence of any intracranial hemorrhage (including suspect of Sub Arachnoid Hemorrhage) or hemorrhagic transformation of brain infarct or other significant abnormality (e.g. tumor, abscess)
  2. Massive stroke, defined as acute parenchymal lesion with effacement of cerebral sulci in over 2/3 of the MCA territory.
  3. Acute stroke due to lacunar infarct as defined by a clinical syndrome (pure motor hemiparesis, ataxic hemiparesis, sensorimotor stroke, dysarthria-clumsy hand syndrome), unless brain imaging demonstrates a relevant lesion > 1.5 cm in size.
  4. Clinical signs and symptoms or evidence for a relevant lesion by neuro-imaging of an acute ischemic stroke in the posterior circulation (Vertebral, Basilar and/or Posterior Cerebral Artery territories), including but not limited to brain-stem findings and/or cerebellar findings and/or isolated homonymous hemianopia or cortical blindness.
  5. Minor stroke with non-disabling deficit or rapidly improving neurological symptoms.
  6. Clinical signs and symptoms or imaging evidence of bilateral stroke.
  7. Treated with IA-rtPA for the current stroke.
  8. Complicated MT procedure (including procedures with more than 3 clot removal attempts (catheter passes), or MT procedure that lasted more than 2 hours)
  9. NIHSS level of consciousness score ≥ 2.
  10. Previous stroke in the last 6 months or previous stroke with existing sequelae or with mRS > 0 for any reason
  11. Pre-existing disability; Pre-existing Modified Rankin Score >1, even if not stroke-related.
  12. Patients with bleeding propensity and/or one of the following: INR≥ 1.8, prolonged activated partial thromboplastin time (aPTT) ≥ 45 sec., platelets count < 75×109/L prior to the implantation/sham procedure.
  13. Known cerebral arteriovenous malformation, cerebral aneurysm.
  14. Seizure at onset.
  15. Blood glucose concentration < 60 mg/dL.
  16. Clinical suspicion of septic embolus.
  17. Uncontrolled hypertension (systolic >185 mmHg and/or diastolic >110 mmHg), demonstrated on each of three repeated measurements taken within one hour regardless of whether or not the patient is taking antihypertensive medications.
  18. Serious systemic infection.
  19. Women known to be pregnant or having a positive or indeterminate pregnancy test.
  20. Patients with other implanted neural stimulator/ electronic devices (pacemakers, etc.).
  21. History of SPG ablation ipsilateral to the stroke side.
  22. Any condition in the oral cavity that prevents implantation of the INS, such as patient is intubated, orthodontics or non-hygienic condition.
  23. Life expectancy < 1 year from causes other than stroke.
  24. Participating in any other therapeutic investigational trial within the last 30 days.
  25. Known sensitivity to any medication to be used during study.
  26. Subjects who have a clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation. Conditions may include: cardiovascular, vascular, pulmonary, hepatic, renal or neurological (other than acute ischemic stroke), or neoplastic diseases, as determined by medical history, physical examination, laboratory tests, or ECG.
  27. Subjects who, in the judgment of the investigator, are likely to be non-compliant or uncooperative during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01874093


Locations
Layout table for location information
Spain
Vall d'Hebron
Barcelona, Spain, 08035
Sponsors and Collaborators
BrainsGate
Investigators
Layout table for investigator information
Study Director: Eyal Shai BrainsGate

Layout table for additonal information
Responsible Party: BrainsGate
ClinicalTrials.gov Identifier: NCT01874093    
Other Study ID Numbers: CLP1050035
First Posted: June 10, 2013    Key Record Dates
Last Update Posted: June 26, 2018
Last Verified: April 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes